Vaccines against Clostridium difficile.

Hum Vaccin Immunother

Novartis Vaccines S.r.L.; Siena, Italy.

Published: June 2015

Clostridium difficile infection (CDI) is recognized as a major cause of nosocomial diseases ranging from antibiotic related diarrhea to fulminant colitis. Emergence during the last 2 decades of C. difficile strains associated with high incidence, severity and lethal outcomes has increased the challenges for CDI treatment. A limited number of drugs have proven to be effective against CDI and concerns about antibiotic resistance as well as recurring disease solicited the search for novel therapeutic strategies. Active vaccination provides the attractive opportunity to prevent CDI, and intense research in recent years led to development of experimental vaccines, 3 of which are currently under clinical evaluation. This review summarizes recent achievements and remaining challenges in the field of C. difficile vaccines, and discusses future perspectives in view of newly-identified candidate antigens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396221PMC
http://dx.doi.org/10.4161/hv.28428DOI Listing

Publication Analysis

Top Keywords

clostridium difficile
8
vaccines clostridium
4
difficile
4
difficile clostridium
4
difficile infection
4
cdi
4
infection cdi
4
cdi recognized
4
recognized major
4
major nosocomial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!